Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer of the Company, will present a corporate update at Rodman & Renshaw's 10th Annual...

Cipher Pharmaceuticals Inc. (TSX: DND) announced that it has been informed that additional time will be required for the U.S. Food and Drug Administration to complete its review of the Company's...

- Third quarter financial results to be released on November 7, 2008 -Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 28 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has appointed John MacInnis as Vice President, Portfolio Development and Licensing. Mr. MacInnis will be responsible for identifying...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2008.Q2 2008 Summary --------------- - Submitted revised...

- Second quarter financial results to be released on Wednesday August 13, 2008 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Aug. 7 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that its revised New Drug Application (NDA) for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that the United States Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-ISOTRETINOIN, the Company's novel...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that a revised New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for CIP-TRAMADOL ER, its...